Search
Castle Biosciences Inc
CSTLAdd to Watchlist
24.110USD
-0.600-2.43%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
730.44MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-2.43%
5 Days
+5.24%
1 Month
+22.32%
6 Months
-37.44%
Year to Date
-38.02%
1 Year
+20.49%
Key Figures
24.710Open
24.980High
175.50KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.58%Turnover Ratio
24.710Prev. Close
24.020Low
3.32MTurnover
40.03P/E Static
1.58P/B
0.00%Div Yield TTM
-2.45%ROA
44.28052wk High
0.70Volume Ratio
18.25MNet Profit
30.30MShares
-0.4158EPS TTM
1.07Beta
-2.85%ROE
14.59052wk Low
3.89%Amplitude
72.80%Gross Margin
730.44MMarket Cap
6.81Reward/Risk
3.11%Risk Rate
TradingKey Stock Score of Castle Biosciences Inc
Currency: USD Updated: 2026-07-02Key Insights
Castle Biosciences Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 15 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 43.56.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Castle Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Castle Biosciences Inc Highlights
StrengthsRisks
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 56.62% year-on-year.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -57.98, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 27.62M shares, decreasing 6.13% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 29.58K shares of this stock.
Analyst Rating
Based on
9
analysts
Strong Buy
Current Rating
43.556
Target Price
+79.09%
Upside Space
Castle Biosciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Castle Biosciences Inc Info
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
Ticker SymbolCSTL
CompanyCastle Biosciences Inc
CEOMaetzold (Derek J)
Websitehttps://castlebiosciences.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.76%
+3.40%
+1.10%
-2.09%
+3.50%Popular Instruments
53030.700
+188.200 (+0.36%)
29552.700
+241.300 (+0.82%)
7505.600
+34.100 (+0.46%)
15060.000
+257.000 (+1.74%)
69451.000
+1303.000 (+1.91%)
6381.100
+28.300 (+0.45%)
68.953
+0.609 (+0.89%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4177.610
+55.700 (+1.35%)
FAQs
What is the current price of Castle Biosciences Inc (CSTL)?
The current price of Castle Biosciences Inc (CSTL) is 24.11.
What is the symbol of Castle Biosciences Inc?
The ticker symbol of Castle Biosciences Inc is CSTL.
What is the 52-week high of Castle Biosciences Inc?
The 52-week high of Castle Biosciences Inc is 44.28.
What is the 52-week low of Castle Biosciences Inc?
The 52-week low of Castle Biosciences Inc is 14.59.
What is the market capitalization of Castle Biosciences Inc?
The market capitalization of Castle Biosciences Inc is 730.44M.
Is Castle Biosciences Inc (CSTL) currently rated as Buy, Hold, or Sell?
According to analysts, Castle Biosciences Inc (CSTL) has an overall rating of STRONG BUY, with a price target of 43.56.
What is the Earnings Per Share (EPS TTM) of Castle Biosciences Inc (CSTL)?
The Earnings Per Share (EPS TTM) of Castle Biosciences Inc (CSTL) is -0.83.